Qiagen launches fast cycling PCR kit

30 October 2006

Venlo, Netherlands-based Qiagen, the world's leading provider of products for pre-analytical sample preparation and molecular diagnostics, launched its new Fast Cycling PCR product line, which it claims substantially accelerates and streamlines the polymerase chain reaction.

According to the firm, the use of its new PCR kit enables users to save up to 75% of the time previously required for the technique. "This significant increase in speed is achieved without compromising the quality of results," stated a company press release.

The kit is compatible with all makes and types of PCR thermal cyclers and with current PCR assays. Unlike other available PCR reagents, the use of Qiagen's product does not require laborious optimization. The kit therefore enables significant time and cost savings without the need for new equipment and sets new standards for speed and accuracy in PCR, says Qiagen.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight